Research illuminating long-term non-progression suggests novel vaccination strategy for HIV

July 18, 2011

A major problem researchers have faced in attempting to develop a vaccine for HIV is that the virus mutates incredibly quickly, which means that its antigens—the target molecules of a vaccine—are moving targets. A comparison of individuals who are able to control HIV without antiretroviral medication with those who are unable to do so suggests that a novel approach to vaccination might work around this problem. The research is published in the July Journal of Virology.

Human DNA contains so-called human endogenous retroviruses (HERVs), which are remnants of ancient retroviruses—genetic fossils—that under normal circumstances sit silently, and always genetically stably, within human DNA. In earlier work, a team of researchers led by Douglas Nixon of the University of California, San Francisco, showed that infection with HIV activates HERVs that lie inside HIV-infected cells in some individuals (but not those in non-infected cells), by interfering with regulatory compounds that normally prevent expression of these HERVs. The activated HERVs produce proteins that attract T cells to the HIV-infected cells, targeting them for destruction. The researchers also showed that the greater T cell response, the lower an individual’s viral load.

In the new research, Devi SenGupta of the University of California, San Francisco et al. extended these findings to include individuals who have long-term chronic HIV-1 infection. They compared the responses of a tiny subset of individuals who are unique in their ability to suppress the indefinitely without the aid of combination therapy to those of patients on highly active antiretroviral therapy (HAART), virologic noncontrollers, immunologic progressors, and uninfected controls. A strong anti-HERV response corresponded to a lower viral load, and a higher CD4+ T cell count. “Interestingly, controllers who lack HLA alleles [critical immune system components] that are associated with protection from HIV-1 disease progression… constituted a large proportion of the subjects with the strongest HERV responses, suggesting that there may be an alternative mechanism of HIV control (such as HERV-specific cytotoxic T ) in these controllers,” the researchers write.

The findings suggest that a vaccination targeting proteins produced by the HERV genes could help the immune system keep HIV in check, says SenGupta. “Our research helps lay the groundwork for developing a new therapeutic or preventive vaccine against . If this leads to a new anti-HIV therapy, millions of lives could be improved all over the world.”

More information: D. SenGupta, R. Tandon, R.G.S. Vieira et al. Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J. Virol. 85:6977-5985

Related Stories

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.